Roche Holding AG
- Country
- 🇨🇭Switzerland
- Ownership
- Public
- Established
- 1896-01-15
- Employees
- 103.6K
- Market Cap
- $270.5B
- Website
- http://www.roche.com
A Study Evaluating the Safety and Efficacy of Venetoclax (GDC-0199) Plus Bendamustine + Rituximab (BR) in Comparison With BR or Venetoclax Plus Rituximab in Participants With Relapsed and Refractory Follicular Non-Hodgkin's Lymphoma (fNHL)
- Conditions
- Follicular Lymphoma
- Interventions
- First Posted Date
- 2014-07-11
- Last Posted Date
- 2019-06-05
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 163
- Registration Number
- NCT02187861
- Locations
- 🇦🇺
Royal Prince Alfred Hospital; Medical Oncology, Camperdown, New South Wales, Australia
🇧🇪Cliniques Universitaires St-Luc, Bruxelles, Belgium
🇧🇪ZNA Stuivenberg, Antwerpen, Belgium
Evaluation of [11C]RO6924963, [11C]RO6931643, and [18F]RO6958948 as Tracers for Positron Emission Tomography (PET) Imaging of Tau in Healthy and Alzheimer's Disease (AD) Participants
- Conditions
- Alzheimer's Disease, Healthy Volunteer
- Interventions
- Drug: [11C]RO6924963Drug: [11C]RO6931643Drug: [18F]RO6958948
- First Posted Date
- 2014-07-11
- Last Posted Date
- 2019-01-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 52
- Registration Number
- NCT02187627
- Locations
- 🇺🇸
Johns Hopkins Universtiy; Radiology Dept, Baltimore, Maryland, United States
🇺🇸Parexel International; Harbor Hospital Center, Baltimore, Maryland, United States
A Single-center Study to Investigate How Quickly and to What Extent a Radioactive Dose of RO5285119 is Absorbed, Metabolized and Eliminated From the Body of Healthy Male Volunteers
- Conditions
- Healthy Volunteer
- Interventions
- Drug: RO5285119
- First Posted Date
- 2014-07-02
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 6
- Registration Number
- NCT02179866
A Study to Assess the Safety and Tolerability of Atezolizumab in Combination With Other Immune-Modulating Therapies in Participants With Locally Advanced or Metastatic Solid Tumors
- Conditions
- Solid Cancers
- Interventions
- First Posted Date
- 2014-06-25
- Last Posted Date
- 2020-05-12
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 158
- Registration Number
- NCT02174172
- Locations
- 🇺🇸
HonorHealth Research Institute - Bisgrove, Scottsdale, Arizona, United States
🇺🇸UCLA, Los Angeles, California, United States
🇺🇸Yale University, New Haven, Connecticut, United States
A Study Comparing the Efficacy and Safety of Etrolizumab With Adalimumab and Placebo in Participants With Moderate to Severe Ulcerative Colitis (UC) in Participants Naive to Tumor Necrosis Factor (TNF) Inhibitors
- Conditions
- Ulcerative Colitis
- Interventions
- First Posted Date
- 2014-06-24
- Last Posted Date
- 2021-07-23
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 358
- Registration Number
- NCT02171429
- Locations
- 🇧🇬
Medical center Medconsult Pleven OOD, Pleven, Bulgaria
🇦🇷Centro de Investigaciones Medicas Mar Del Plata, Mar del Plata, Argentina
🇧🇬DCC Sv. Pantaleymon OOD, Pleven, Bulgaria
A Study of Oral Vismodegib for the Treatment of Idiopathic Pulmonary Fibrosis (IPF)
- First Posted Date
- 2014-06-20
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Registration Number
- NCT02168530
A Single Center Study to Evaluate the Penetration of RO7033877 Into the Lung in Healthy Volunteers
- Conditions
- Healthy Volunteer
- Interventions
- Drug: RO7033877 + Bronchoscopy
- First Posted Date
- 2014-06-17
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 32
- Registration Number
- NCT02165293
A Two-part, Single-dose, Randomized Study to Evaluate the Safety of Supra-therapeutic Doses of RO7033877 and to Investigate the Effect of RO7033877 on the QTc Interval
- Conditions
- Healthy Volunteer
- First Posted Date
- 2014-06-17
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 64
- Registration Number
- NCT02165332
Extension Study Evaluating the Safety and Efficacy of Subcutaneous Tocilizumab (RoActemra/Actemra) Administration in Systemic and Polyarticular-Course Juvenile Idiopathic Arthritis
- First Posted Date
- 2014-06-17
- Last Posted Date
- 2022-02-23
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 82
- Registration Number
- NCT02165345
- Locations
- 🇺🇸
Duke University, Durham, North Carolina, United States
🇲🇽Hospital Infantil de México "Federico Gomez"; Rheumatology, Mexico, Mexico
🇲🇽Hospital Universitario Dr. Jose Eleuterio Gonzalez; Pediatria, Monterrey, Mexico
A Study of the Efficacy and Safety of Etrolizumab Treatment in Maintenance of Disease Remission in Ulcerative Colitis (UC) Participants Who Are Naive to Tumor Necrosis Factor (TNF) Inhibitors
- First Posted Date
- 2014-06-17
- Last Posted Date
- 2021-08-19
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 359
- Registration Number
- NCT02165215
- Locations
- 🇺🇸
Shafran Gastroenterology Center, Winter Park, Florida, United States
🇺🇸Northwestern University-Feinberg School of Medicine; Division of Gastroenterology and Hepatology, Chicago, Illinois, United States
🇺🇸Southwest Gastroenterology, Oak Lawn, Illinois, United States